A study of iptacopan for C3G patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medicine called iptacopan for people with a kidney condition called C3G. It looks at how the disease progresses in those who have taken or are currently taking iptacopan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with C3G, a kidney disease (a biopsy should confirm this if you had one).
- You are 18 years or older.
- You have had C3G for at least 6 months before joining the study.
- You are taking or have taken iptacopan for C3G within the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This study tests an experimental drug called SGB-9768 for people with certain kidney diseases that involve complement protein deposits. The goal is to see if it can reduce kidney damage and protein loss in urine.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This study tracks adults with C3G (a rare kidney disease where the immune system damages the filtering units) who have already received iptacopan (a new medicine) through an early access program in Spain. Researchers want to understand how well this treatment works and its safety in real-world patients.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.